Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_assertion type Assertion NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_head.
- NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_assertion description "[In summary, findings herein are the first to demonstrate a functional TLR-signaling pathway specifically in GCTs, and indicate that in contrast to OSE-derived cancers, inhibition of NF-?B does not sensitize GCTs to TRAIL or cisplatin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_provenance.
- NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_assertion evidence source_evidence_literature NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_provenance.
- NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_assertion SIO_000772 21616060 NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_provenance.
- NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_assertion wasDerivedFrom befree-20150227 NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_provenance.
- NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_assertion wasGeneratedBy ECO_0000203 NP589973.RAiDP6lBMLGMnJs2W8x-Wn6LLMQcSdFoOe9-gSX-GnuDM130_provenance.